Transactions

Financings

Rubicon Research

Equity Sale

$33 million

November 2016

North America

SciDose

Partial Sale of Royalties and Milestones

$40 million

September 2016

North America

Academic Inventor

Sale of Phase II Enzyme Replacement Royalty

August 2016

North America

Topix Pharmaceuticals

Equity Investment

July 2016

North America

Undisclosed

Credit Facility

$100 million

February 2016

North America

Amerigen

Senior Credit Facility

$15 million

December 2015

North America

Crown Laboratories

Senior Term Loan from Hayfin Advisors

$20 million

September 2015

North America

PDI

Acquisition Financing from SWK Holdings

$20 million

December 2014

North America

Probiodrug

IPO Advisory

$30 million

October 2014

Europe

DBV Technologies

Global Offering Advisory

$116 million

October 2014

Europe

ABT Molecular Imaging

Synthetic Royalty Financing from SWK Holdings

$10 million

October 2014

North America

Trimel

Acquisition Financing from MidCap Financial

$25 million

July 2014

North America

Compugen

Follow-on Offering

$72.5 million

February 2014

Asia, Africa, MidEast, Latin America

DBV Technologies

Financial Advisor in Private Placement

€29,900,000

November 2013

Europe

Boulder Diagnostics

Financial advisor on a private equity financing

August 2013

North America

Ventrus Biosciences

Financial Advisor in a follow-on financing for GI company

July 2011

North America

DBV Technologies

Advisor in a private placement

DBV Technologies, creator of Viaskin®, a new standard in the treatment of allergy, launched a private placement for a target amount of circa €25 million, which €14 million will be in the form of new shares and€11 million will be in the form of existing shares. DBV Technologies may extend this amount but will in no event place more than 4,722,464 shares consisting of new shares issued by means of a capital increase without shareholders' preemptive rights and existing shares sold by certain shareholders. The shares will be offered in a Private Placement conducted by way of an accelerated bookbuilding. The issuance of new shares by the Company is intended to raise gross proceeds of around €14 million, which will be used to provide additional funding to the Company to finance its development strategy.

Press Release